Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.
Also called NCT07684469
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 300 participants
- Sponsor
- Registry
-
NCT07684469
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Not reported
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07684469. Randomized; no masking; primary purpose treatment. Start 2026-10-31 (anticipated); primary completion 2028-02-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Comparative Assessment of Inclisiran on Top of Standard of Care Versus Standard of Care Alone for LDL-C Evaluation in Acute Coronary Syndrome Patients in Saudi Arabia
- Condition
- Acute Coronary Syndrome
- Intervention (Drug)
- inclisiran
- Intervention (Drug)
- SOC
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct07684469- Content hash
8d4436591336ea0dea2d0d376035455823bae47ce6ff2dcf02b88843a44dfc88